Description: N4 Pharma Plc, a specialist pharmaceutical company, develops silica nanoparticle delivery systems to enhance the cellular delivery of cancer treatments, gene therapy, and vaccines in the United Kingdom. It develops Nuvec, which offers silica nanoparticles with irregular surface structure and polyethyleneimine that traps and protects nucleic acid; and Liptide, a platform to deliver a proprietary siRNA sequence to silence a fibrotic gene for the treatment of glaucoma. The company was incorporated in 1979 and is based in London, the United Kingdom.
Home Page: www.n4pharma.com
60 Gracechurch Street
London,
EC3V 0HR
United Kingdom
Phone:
44 1332 690061
Officers
| Name | Title |
|---|---|
| Mr. Nigel James Theobald | Founder, CEO & Executive Director |
| Dr. David Templeton | Executive Director & Technical Director |
| Mr. Luke Sebastian Cairns | Executive Director |
| Rob Harris | Head of CMC Development |
| Dr. Andrew Leishman | Consultant |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.262 |
| Price-to-Sales TTM: | 529.1432 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 5 |